MPM BioImpact’s Travere Therapeutics TVTX Stock Holding History

MPM BioImpact’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.8M	Sell	1,122,731 -10,634	-0.9%	-$471K	3.89%	7
2026 Q1	$33.7M	Buy	+1,133,365	New	+$33.9M	2.6%	14
2023 Q4	–	Sell	-552,846	Closed	-$4.94M	–	34
2023 Q3	$4.94M	Hold	552,846	–	–	1.32%	25
2023 Q2	$8.49M	Buy	552,846 +239,204	+76%	+$4.35M	1.71%	19
2023 Q1	$7.05M	Buy	313,642 +31,931	+11%	+$679K	1.83%	15
2022 Q4	$5.92M	Buy	281,711 +5,251	+2%	+$111K	1.54%	18
2022 Q3	$6.81M	Sell	276,460 -1,490	-0.5%	-$38.5K	1.61%	17
2022 Q2	$6.74M	Hold	277,950	–	–	1.87%	14
2022 Q1	$7.16M	Sell	277,950 -9,943	-3%	-$264K	1.92%	14
2021 Q4	$8.94M	Sell	287,893 -18,622	-6%	-$524K	1.63%	16
2021 Q3	$7.43M	Buy	+306,515	New	+$5.63M	1.15%	20

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's TVTX Position: Q2 2026 in Review

MPM BioImpact reduced its Travere Therapeutics (TVTX) stake by 0.94% in Q2 2026, selling an estimated $471K and leaving 1,122,731 shares worth $63.8M. The position accounts for 3.89% of the portfolio, ranked #7.

MPM BioImpact first reported a position in TVTX in Q3 2021 and has held it in 11 quarters since. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

MPM BioImpact held 1,122,731 shares of Travere Therapeutics worth $63.8M as of Q2 2026.
MPM BioImpact sold 10,634 Travere Therapeutics shares in Q2 2026, an estimated $471K.
Travere Therapeutics made up 3.89% of MPM BioImpact's portfolio in Q2 2026, its #7 holding.
MPM BioImpact first reported a position in Travere Therapeutics in Q3 2021 and has held it in 11 quarters since.
319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.